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SIMULTANEOUS MFN2 AND GDAP1 MUTATIONS
CAUSE MAJOR MITOCHONDRIAL DEFECTS IN A
PATIENT WITH CMT
Mutations in the MFN2 gene are associated with
Charcot-Marie-Tooth disease type 2A (CMT2A), a
dominant axonal CMT, whereas mutations in GDAP1
are associated with recessive demyelinating CMT
(CMT4A), recessive axonal CMT (AR-CMT2), and
dominant axonal CMT (CMT2K). Both proteins are
involved in energy metabolism and dynamics of the mi-
tochondrial network.1-3 We have previously reported
that, in fibroblasts from patients with CMT, MFN2
mutations resulted in a mitochondrial energy coupling
defect,4,5 whereas dominant mutation in GDAP1 re-
sulted in defective complex I activity.6
In this study, we investigated mitochondrial bioen-
ergetics from a severely affected patient with CMT har-
boring combined mutations in both GDAP1 and
MFN2 genes.
Methods. For details, see e-Methods on the Neurol-
ogy® Web site at www.neurology.org.
Patients. Patient II-5 (figure 1A), a 71-year-old
woman of Spanish origin, had severe distal muscle
weakness from the age of 3, becoming wheelchair-
bound during her third decade. Clinical examination
showed severe weakness of limbs with proximal and dis-
tal amyotrophy, tactile and nociceptive hypoesthesia
with a gloves-and-socks distribution, and abolition of
the limb reflexes. She had pes cavus and moderate vocal
cord paresis. Electrophysiologic studies (table e-1) indi-
cated a severe axonal neuropathy characterized by a ma-
jor reduction of motor action potential in the left
median nerve (0.1 mV) with a slightly reduced motor
conduction velocity (43 m/s).
Patient II-8, her 56-year-old brother, presented with a
mild CMT2 clinical phenotype. Electrophysiologic exam-
ination showed a sensory axonal neuropathy (table e-1).
His 2 daughters, aged 19 and 25 years, are currently
asymptomatic. Patient II-2, who had a phenotype compat-
ible with CMT, had died of respiratory failure.
Results. Mutation analysis. Patient II-8 and his asymp-
tomatic daughter (III-15) were found to be heterozy-
gous for the pathogenic p.R468H mutation in MFN2,
previously described.7 Individuals II-3, II-4, and II-7
were heterozygous for the p.Q163X mutation in
GDAP1. Patient II-5 was found to be heterozygous for
the p.R468H mutation in MFN2 and homozygous for
the p.Q163X mutation in GDAP1 (figure 1A).
Mitochondrial imaging and biochemistry. No alteration
of the mitochondrial network was revealed in MFN2:
p.R468H fibroblasts and in MFN2:p.[R468H]
GDAP1:p.[Q163X][Q163X] fibroblasts (figure e-1).
In patient II-5 fibroblasts, a more severe energy
coupling defect than in MFN2 patients was discov-
ered with 85% reduction of the ATP/O ratio com-
pared to controls (figure 1Ba). Mitochondrial
uncoupling was associated with a 65% decrease of
mitochondrial ATP production that was absent in
fibroblasts with a single MFN2 mutation (figure
1Bb). Similarly to patients with dominant mutation
in GDAP1, fibroblasts carrying mutations in both
MFN2 and GDAP1 showed a 40% reduction of
complex I activity compared with MFN2 patients
and controls (see malate pyruvate complex I sub-
strates value on figure 1Bc, and enzymatic complex
measurements on figure 1Bd).
Discussion. We report a patient with CMT carry-
ing simultaneous mutations in GDAP1 and MFN2.
Initially, this patient was found to be heterozygous
for the p.R468H mutation in MFN2. Individuals
carrying this mutation usually have mild CMT phe-
notype or are asymptomatic.7 Hence the sole pres-
ence of this mutation could not be responsible for the
severe clinical phenotype,7 suggesting the need for
further genetic analysis, which revealed the existence
of the p.Q163X homozygous mutation in GDAP1 as
an explanation of the clinical severity.
We have previously reported that MFN2 muta-
tions resulted in an energy coupling defect with nor-
mal mitochondrial ATP production,4,5 whereas
dominant mutation in GDAP1 resulted in defective
complex I activity with a decrease in ATP production
when complex I substrates (malate and pyruvate)
were used.6 A compensatory mechanism was postu-
lated since the production of ATP was normal when
succinate, the complex II substrate, was used (figure
1Bb). In a patient carrying mutations in GDAP1 and
MFN2, we showed defective complex I activity as
well as severe mitochondrial uncoupling. Interest-
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ingly, the reduction of complex I activity was similar
to that of fibroblasts with the dominant GDAP1 mu-
tation. In addition, the ATP production with com-
plex I and complex II substrates was significantly
reduced compared to fibroblasts harboring either the
MFN2 or GDAP1 mutations alone (figure 1Bb).
These findings underscore the role of GDAP1 in the
function of respiratory complex I and suggest that
this combination of mutations has biochemical
deleterious synergistic effects. In MFN2 patients,
the mitochondrial uncoupling was associated with
a higher respiratory rate involving complex II,
serving as a compensatory mechanism (MPS value,
figure 1Bc).5 However, in MFN2-GDAP1 double
mutant fibroblasts, the complex I defect may have
limited such compensation, leading to a decrease
in ATP production.
Finally, our study suggests that the clinical heter-
ogeneity of CMT may be related to the simultaneous
presence of mutant alleles in different CMT genes,
emphasizing the need for extensive genetic investiga-
tion to provide accurate diagnosis.
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Figure 1 Genetic and biochemical findings
(A) Pedigree of a family with Charcot-Marie-Tooth disease (CMT) showing the distribution of the nonsense p.Q163X muta-
tion in GDAP1 and the missense p.R468H mutation in MFN2. Clear circles: unaffected females; clear squares: unaffected
males; black circle: affected female; and black squares: affected males; m: mutant alleles; and wt: wild-type alleles. The
arrow indicates the proband. (B) Biochemical findings. (a) Coupling efficiency (ATP/O), i.e., rate of ATP produced per nano-
mole of oxygen consumed with malate (M), pyruvate (P), and succinate (S) as substrates. (b) Mitochondrial ATP production
with MPS. (c) Rate of oxygen consumption with malate pyruvate (MP) or MPS, or with S/Rotenone (R), a mitochondrial
complex I inhibitor. (d) OxPhos enzymatic activities were normalized with the citrate synthase (CS) activity, a reference
mitochondrial content. The results are expressed as mean values  SD of 3 independent measurements. Statistical signif-
icance levels applied to the control, MFN2, and GDAP1 groups: *p  0.05; **p  0.01. Control group n  7; MFN2 group n 
10 (7 different MFN2 mutations); GDAP1 group n  3 (p.C240Y mutation). See e-Methods for more information.
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INCREASING INCIDENCE OF MYASTHENIA
GRAVIS AMONG ELDERLY IN BRITISH
COLUMBIA, CANADA
Presence of anti-acetylcholine receptor (anti-AChR)
antibodies is highly specific for myasthenia gravis
(MG). These antibodies are detected in 85%–95%
of sera from patients with generalized MG and 40%–
70% of patients with ocular MG.1
An increasing incidence of MG, especially in the
elderly population, has been described in Japan, the
United Kingdom, and Denmark.2-4 Recent studies
have also focused on the epidemiology of anti-AChR
antibody seropositivity as a surrogate marker of
MG.4-6 The Neuro-Immunology Laboratory at the
University of British Columbia is the sole laboratory
in British Columbia (BC), Canada, offering anti-
AChR antibody testing for clinical diagnosis.
The aims of this study were to evaluate the inci-
dence and epidemiologic characteristics of anti-
AChR antibody seropositivity in BC and to examine
changes in incidence over time.
Methods. We performed a population-based study
of the incidence of anti-AChR antibody-seropositivity
in BC for the 25-year period of January 1, 1984, to
December 31, 2008. Incident cases were ascertained by
retrospectively identifying all first-time seropositive
tests. A positive anti-AChR antibody test was necessary
and sufficient for a patient to be included as a case.
During these 25 years, BC’s population increased from
2,947,181 to 4,381,603.
Data analysis. Incidence was defined as the annual
number of first-time anti-AChR seropositive cases. Inci-
dence rates (IRs) were calculated per 1 million inhabit-
ants based on annual July population estimates
(BCStats, www.bcstats.gov.bc.ca). Cases were stratified
into 4 age groups based on age at the first positive test:
19, 20–44, 45–64, and 65 years. Age- and sex-
stratified IRs were calculated based on population
estimates of the corresponding age and sex group.
Ninety-five percent confidence intervals (95% CI) were
calculated using the Poisson distribution.
Results. Between January 1984 and December 2008,
we identified 1,243 new anti-AChR seropositive indi-
viduals (648 women, 587 men, 8 unknown). The age at
the first positive serum sample in women had a bimodal
distribution with peaks at 45–55 and 70–85 years,
whereas in men the distribution had a single peak at
70–80 years (figure e-1 on the Neurology® Web site at
www.neurology.org). This age distribution resembles
previous observations on the age at onset of MG.3,5 The
average annual IR of first-time anti-AChR seropositive
cases for the period of 1984–2008 was 13.2 per year per
million (95% CI 12.5–14.0).
Mean annual IRs of the 19, 20–44, and 45–64
age groups did not change substantially over these 25
years: 3.6/year/million (95% CI 2.9–4.5), 7.7 (95%
CI 6.8–8.7), and 16.8 (95% CI 15.1–18.7) (figure
1). In contrast, annual IRs of the 65 age group
significantly increased from 21.4 during 1984–1988
(95% CI 15.2–29.3) to 52.9 during 2004 –2008
(95% CI 45.1–61.9).
Sex-adjusted IRs significantly increased for both
men and women 65 from 1984–1988 to 2004–
2008 as follows: from 26.4 (95% CI 16.3–40.4) to
63.5 (95% CI 50.8–78.7) for men and from 17.6
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for women (figure e-2). Moreover, our results also
indicate that the incidence of anti-AChR seropositiv-
ity in the 65 age group has increased at a signifi-
cantly greater rate than the rate of increase in the
proportion of people 65 in the BC population
(figure e-2).
Discussion. The presence of anti-AChR antibodies
is considered a good surrogate marker for the diagno-
sis of MG. The overall average anti-AChR seroposi-
tivity IR of 13.2 per million in BC is among the
highest reported, with only a higher IR of 18 per
million in the United Kingdom.3
Our data indicate that the probability of becom-
ing anti-AChR seropositive significantly increases
with age (figure 1). Previous studies have also indi-
cated an increasing incidence of elderly onset MG.2-4,7
From 1984 to 2008, the incidence of anti-AChR se-
ropositivity in BC remained relatively constant in
younger age groups, but more than doubled in the
65 population for both men and women (figures 1
and e-2). This trend cannot simply be attributed to
increasing longevity and an aging population, since
our results show that the incidence of anti-AChR se-
ropositivity in the 65 age group has increased at a
significantly greater rate than the rate of increase in
the proportion of people 65 in BC (figure e-2).
One can argue that our observations are due to
greater awareness of MG or increased anti-AChR an-
tibody testing. However, the IRs of the 3 younger age
groups have remained stable. Other contributing fac-
tors could be improved diagnosis of elderly patients
or environmental and lifestyle changes.
Prominent features of our study include a central-
ized source of data, a large sample size which renders
IRs more reliable, and data spanning 25 years. This
study confirms the trend of increasing incidence of
elderly onset anti-AChR seropositive MG observed
in previous studies and its results are important for
future health care planning.
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